A multidisciplinary team of more than 50 scientists from the University of California San Francisco, UC Berkeley and two affiliated research hubs conducted the research, which has not yet been peer-reviewed. Researchers spent the past few weeks comparing the performance of all commercially available antibody tests for COVID-19.
They found just one test never produced a false positive, and two others avoided false positives 99 percent of the time. However, these three tests still only detected antibodies in COVID-19 patients 90 percent of the time.
Of the remaining tests, four had false-positive rates in the 11 percent to 16 percent range. Most others fell at about 5 percent.
While the research is still preliminary and subject to revisions, NYT noted the findings could complicate plans to reopen parts of the U.S. if antibody test results are not accurate.
To view the full article, click here.
More articles on public health:
22 states resuming elective surgeries
Pandemic was taking hold in US earlier than officials realized, researchers say
Most states not testing enough to safely reopen, analysis suggests
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
